A new receptor tyrosine kinase inhibitor, icotinib, for patients with lung adenocarcinoma cancer without indication for chemotherapy

Zheng,Xiao; Liu,Guan; Wang,Shengye; Zhang,Yunli; Bao,Wenlong; Deng,Dehou; Mao,Weiming; Fang,Meiyu

doi:10.3892/ol.2014.2386

A new receptor tyrosine kinase inhibitor, icotinib, for patients with lung adenocarcinoma cancer without indication for chemotherapy

Authors:
- Xiao Zheng
- Guan Liu
- Shengye Wang
- Yunli Zhang
- Wenlong Bao
- Dehou Deng
- Weiming Mao
- Meiyu Fang
View Affiliations

Affiliations: Department of Radiation Oncology, Zhejiang Cancer Hospital, Hangzhou, Zhejiang 310021, P.R. China, Department of Surgical Oncology, Zhejiang Cancer Hospital, Hangzhou, Zhejiang 310021, P.R. China, Department of Integrated Chinese Traditional Medicine and Western Medicine, Zhejiang Cancer Hospital, Hangzhou, Zhejiang 310021, P.R. China
Published online on: July 28, 2014 https://doi.org/10.3892/ol.2014.2386
Pages: 1563-1566

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Epidermal growth factor receptor (EGFR) is an important therapeutic target in lung cancer. Gefitinib and erlotinib, two reversible EGFR receptor tyrosine kinases inhibitors (TKIs), have been approved for the treatment of patients with metastatic non small‑cell lung cancer. Icotinib, which is a selective EGFR‑TKI, provides a similar efficacy to gefitinib. The present study aimed to investigate the survival and safety of icotinib in patients with lung adenocarcinoma with a poor performance status (PS). A total of 42 cases of lung adenocarcinoma, including 35 females and 7 males, were enrolled. Icotinib was used as the first‑line of treatment due to poor PS of the patient or a more advanced age. Icotinib (125 mg) was orally administered three times per day. The overall response rate and disease control rates were 33.3 and 85.7%, respectively. The median survival time was 13.0 months (95% CI, 5.6‑20.4), The median progression‑free survival time was 7.0 months, and the 1‑year survival rate was 71.4%. A total of 79% of patients had an improved PS following icotinib treatment. Grade 1 to 2 rashes and diarrhea were the most frequent side effects. One patient succumbed during the study due to interstitial pneumonia. In conclusion, this is the first study indicating that patients with lung adenocarcinoma and poor PS may benefit from first‑line icotinib therapy, but should be cautious of the occurrence of interstitial lung disease.

View Figures

View References

1	Jemal A, Bray F, Center MM, et al: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011.
2	Fang M, Wang S, Zheng Y, et al: Maintenance therapy with oral etoposide following first-line docetaxel-cisplatin chemotherapy in metastatic non-small cell lung cancer patients. Bangladesh J Pharmacol. 7:192–198. 2012.
3	Sharma S, Bell D, Settleman J and Haber DA: Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer. 7:169–181. 2007.
4	Fukuoka M, Yano S, Giaccone G, et al: Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial). J Clin Oncol. 21:2237–2246. 2003.
5	Kris MG, Natale RB, Herbst RS, et al: Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA. 290:2149–2158. 2003.
6	Maemondo M, Inoue A, Kobayashi K, et al: Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 362:2380–2388. 2010.
7	Mitsudomi T, Morita S, Yatabe Y, et al: Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 11:121–128. 2010.
8	Zhao Q, Shentu J, Xu N, et al: Phase I study of icotinib hydrochloride (BPI-2009H), an oral EGFR tyrosine kinase inhibitor, in patients with advanced NSCLC and other solid tumors. Lung Cancer. 73:195–202. 2011.
9	Tan F, Shen X, Wang D, et al: Icotinib (BPI-2009H), a novel EGFR tyrosine kinase inhibitor, displays potent efficacy in preclinical studies. Lung Cancer. 76:177–182. 2012.
10	Liu D, Jiang J, Hu P, et al: Quantitative determination of icotinib in human plasma and urine using liquid chromatography coupled to tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 877:3781–3786. 2009.
11	Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 92:205–216. 2000.
12	National Cancer Institute. National Cancer Institute Common Toxicity Criteria. http://ctep.cancer.gov/protocolDevelopment/electronic.applications/docs/ctcaev3.pdf. Accessed June 22, 2014
13	Thatcher N, Chang A, Parikh P, et al: Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet. 366:1527–1537. 2005.
14	Lee DH, Han JY, Yu SY, et al: The role of gefitinib treatment for Korean never-smokers with advanced or metastatic adenocarcinoma of the lung: a prospective study. J Thorac Oncol. 1:965–971. 2006.
15	Inoue A, Suzuki T, Fukuhara T, et al: Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations. J Clin Oncol. 24:3340–3346. 2006.
16	Asahina H, Yamazaki K, Kinoshita I, et al: A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations. Br J Cancer. 95:998–1004. 2006.
17	Sunaga N, Tomizawa Y, Yanagitani N, et al: Phase II prospective study of the efficacy of gefitinib for the treatment of stage III/IV non-small cell lung cancer with EGFR mutations, irrespective of previous chemotherapy. Lung Cancer. 56:383–389. 2007.
18	Sutani A, Nagai Y, Udagawa K, et al: Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp. Br J Cancer. 95:1483–1489. 2006.
19	Paz-Ares L, Sanchez JM, García-Velasco A, et al: A prospective phase II trial of erlotinib in advanced non-small cell lung cancer (NSCLC) patients (p) with mutations in the tyrosine kinase (TK)domain of the epidermal growth factor receptor (EGFR). J Clin Oncol. 24:369s2006.
20	Sequist LV, Martins RG, Spigel D, et al: iTARGET: A phase II trial to assess the response to gefitinib in epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) tumors. J Clin Oncol. 25:386s2007.
21	O’Connell J, Kris MG, Gralla RJ, et al: Frequency and prognostic importance of pretreatment clinical characteristics in patients with advanced non-small cell lung cancer treated with combination chemotherapy. J Clin Oncol. 4:1604–1614. 1986.
22	Radzikowska E, Glaz P and Roszkowski K: Lung cancer in women: age, smoking, histology, performance status, stage, initial treatment, and survival. Population-based study of 20 561 cases. Ann Oncol. 13:1087–1093. 2002.